Join fellow biotech professionals for this exclusive quarterly series that brings together the area biotech community for an inside look at local biotech advances, a chance to share expertise as well as network with other scientists and entrepreneurs in the area.
Advanced Technology Research Facility
8560 Progress Drive
Frederick, MD, 21702
Data Science and the Fight Against Cancer [Dr. Eric Stahlberg, Presenter]
Scientists are harnessing the power of supercomputers, vast data repositories, and leading-edge technologies to accelerate the fight against cancer. Time is of the essence. It now takes five or six years of preclinical development to get a candidate cancer drug into clinical trials. Failure rates are high. What if we could cut that timeline to about a year? What if candidate drugs stood a better chance of success? Learn how federal national laboratories are collaborating with big pharma and academic researchers to transform drug discover from a slow, sequential, and low-success process into a rapid, integrated, and patient-centric model. The talk will touch on bioinformatics analysis, image processing, natural language processing, molecular dynamics simulations and machine learning.
Large-Scale Scientific Data [Uma Mudunuri, Presenter]
Data science has an enormous potential to influence the direction and pace of biomedical research. The presentation will cover the current state of data science, challenges faced by the biomedical community, and showcase technical innovations derived by successfully employing data science methodologies. These include generating interactive visual dashboards for clinical analytics and cohort analysis on thousands of patients, integrating and automating biological annotations of many types and species, and automated text mining and analytics on variant and gene-related searches in literature.
What Your Statisticians Wish They Could Tell You [Dr. Ena Bromley, Presenter]
With increasingly complex data, there is a growing need for effective communication between clinical investigators and analytical experts. This presentation will cover key aspects that could impact the successful design, analysis and interpretation of clinical studies. Aspects such as missingness, biases, and heterogeneity of data will be discussed. Within the context of -omic studies, the influence of phenotypic measurements on the interpretation of biomarker data will be explored and discussed.
Interested in Attending?
Simply click the registration button below and fill out the form. See you there!
Dr. Stahlberg is director of Biomedical Informatics and Data Science at the Frederick National Laboratory for Cancer Research. He holds a Ph.D. in computational chemistry from The Ohio State University. He has been instrumental in establishing the Frederick National Laboratory’s high- performance computing initiative and in assembling scientific teams across multiple, complex organizations to advance predictive oncology. Dr. Stahlberg serves in a leadership role for a number of ongoing partnerships, including a major collaboration between the National Cancer Institute and the Department of Energy that aims to accelerate progress in precision oncology and computing, and a national consortium with the mission of accelerating the drug discovery process.
Uma Mudunuri is deputy director of Advanced Biomedical Computational Science group at the Frederick National Laboratory. Ms. Mudunuri leads the data solutions and systems biology group, which focuses on providing flexible, modular and disease agnostic solutions for simple to large scale clinical genomic challenges. Her current areas of focus are text analytics, clinical-genomic integration, variant impact analysis, data search and access platforms, and holistic integrative informatics. Ms. Mudunuri holds a master’s degree in bioinformatics from University of Pennsylvania and a master’s degree in biotechnology from University of Pune.
Dr. Ena Bromley is Chief Scientific Officer, President and co-founder of BioStat Solutions, Inc. (BSSI). Trained as both a statistical geneticist and genetic epidemiologist, she leads a team of bioinformaticists and biostatisticians towards developing technology that is tailored to the need of the clinical investigator. She focuses on not only the statistical analyses, but more importantly the interpretation of actionable findings in complex diseases with respect to device, biologic and drug discovery and response. Dr. Bromley has experience in representing clients to regulatory agencies in the US and abroad and has served on various panels and working groups to develop analytical methodologies supporting the design, analysis and interpretation of clinical studies. Dr. Bromley received her Ph.D. in statistical genetics from the University of Nebraska, Lincoln, NE. She holds both, a Master of Science degree in statistical genetics and a Bachelor of Science degree in genetics from the University of Pretoria in Pretoria, South Africa. She completed her post-doctoral fellowship at the Genetic Epidemiology Branch at the National Cancer Institute in Bethesda, MD.